Recently added

Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer

Ambrosini, Margherita; Rousseau, Benoit; Manca, Paolo; Artz, Oliver; marabelle, aurelien; André, Thierry; Elez, Elena (Elsevier, 2024-07)

Use of ctDNA in early breast cancer: analytical validity and clinical potential

Panet, François; Vivancos, Joan; Vivancos, Ana; Oliveira, Mafalda; Papakonstantinou, Andri; Borrell, Maria (Nature Research, 2024-06-19)

Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study

Baranda, Joaquina; Sullivan, Ryan; Doger, B; Santoro, Armando; Barve, Minal ; Robbrecht, Debbie; Vieito , Maria (Wiley, 2024-06)

Impact of coadministration of proton-pump inhibitors and palbociclib in hormone receptor-positive/HER2-negative advanced breast cancer

Pérez-García, José Manuel; dalenc, florence; Ruiz-Borrego, Manuel; Di Cosimo, Serena; Bellet Ezquerra, Meritxell; Gil Gil, Miguel J. (Elsevier, 2024-06-11)

First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN

MARTINEZ JAÑEZ, NOELIA; Luis, Manso; Henao, Fernando; Antón Torres, Antonio; Bellet Ezquerra, Meritxell; Morales, Serafin (Springer, 2024-07)

Scientia. Dipòsit d'Informació Digital del Departament de Salut

VHIO - Articles científics: Recent submissions

Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer

Use of ctDNA in early breast cancer: analytical validity and clinical potential

Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study

Impact of coadministration of proton-pump inhibitors and palbociclib in hormone receptor-positive/HER2-negative advanced breast cancer

First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN

Scientia. Dipòsit d'Informació Digital del Departament de Salut

VHIO - Articles científics: Recent submissions

Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer ﻿

Use of ctDNA in early breast cancer: analytical validity and clinical potential ﻿

Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study ﻿

Impact of coadministration of proton-pump inhibitors and palbociclib in hormone receptor-positive/HER2-negative advanced breast cancer ﻿

First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN ﻿

Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer

Use of ctDNA in early breast cancer: analytical validity and clinical potential

Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study

Impact of coadministration of proton-pump inhibitors and palbociclib in hormone receptor-positive/HER2-negative advanced breast cancer

First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN